BioMarin Pharmaceutical

Now, the other one didn't do so much.

The Biomarin, huh? It tried to go up there.

Is it just having a dip or is it party over for that? Because that baby went from 50 to 72, then back here to 60 something.

But does it look like it has another leg in it or?

The regulatory environment continues to evolve with notable challenges.

BioMarin has discontinued Phase II development of Voxzogo in Noonan syndrome due to shifting treatment landscapes, illustrating the dynamic nature of therapeutic development.

Similarly, Novartis has halt on its TREM-2 stabilizer after a Phase II failure in ALS research points to the complexities inherent in neurodegenerative disease studies.

Mayat Pharma faced a setback when its appeal was rejected regarding the EMA's negative opinion on its graft versus host disease candidate, Zerviteg.

It plans to take that combination into Phase IIa in the first quarter of twenty twenty-seven.

At Biomarin, a different kind of development stop.

The company has discontinued Voxzogo development in children with Noonan syndrome, where it was running a Phase II study.

Biomarin cites study feasibility and the current treatment landscape, expressly not safety or efficacy.

This ends the Noonan expansion effort.

It doesn't withdraw Voxzogo's existing indication or the separate hypochondroplasia filing.

So part of it, yes.

But my first job in bioanalysis was at BioMarin, which is a rare disease, and under Gary Taniguchi.

And why that job? I had made a determination at my previous job, ALSA, I had a mentor who told me, you know what, Jolene, you really should look at development jobs, not research jobs.

Because what frustrates you about research jobs is that you have a less direct connection to patients.

And you need people like that in your life who say, you know what, it's not like you're bad at It's just I think you would like this other thing better.

And so when I was laid off from that job, I started looking for development jobs.

I had a connection through AWIS who had recently started at BioMarin.

I saw a job posting.

The release doesn’t yet show how much patients gained over placebo.

On the regulatory front, BioMarin has completed its US supplemental submission for vosoritide in hypochondroplasia, a genetic condition affecting bone growth.

Marketed as Voxzogo, the drug already has FDA accelerated approval to increase linear growth in children with achondroplasia and open growth plates.

The new request concerns a different condition.

BioMarin says hypochondroplasia has no FDA- or EMA-approved medicine.

The Phase 3 result reported in May was an extra two point thirty-three centimeters of annualized growth versus placebo.

Today’s update confirms the completed submission as the study is published in NEJM Evidence.

BioMarin is seeking to extend an existing growth medicine to this separate patient group.

11.

Biomarin acquires Alesta for $275 million to strengthen bone and skeletal disease portfolio.

The deal puts Biomarin in closer competition with larger companies including AstraZeneca in rare bone disease.

Number 12, Leo Pharma signed a deal with Tanabe worth up to $435 million to continue the trend of companies looking externally for pipeline assets rather than relying exclusively on internal R&D.

Number 13, Sanofi's KeyMap bad falters.